Draft Patents (Amendment), Rules, 2023
The Ministry of Commerce and Industry, under the Department for Promotion of Industry and Internal Trade, has introduced draft amendments to the Patents Rules, 2003. These drafts detail various changes
The Ministry of Commerce and Industry, under the Department for Promotion of Industry and Internal Trade, has introduced draft amendments to the Patents Rules, 2003. These drafts detail various changes
Ranbaxy Laboratories, Dr Reddy's Laboratories, Nicholas Piramal and other pharmaceutical companies are betting on inlicensing or strategic marketing tie-ups to help grow local sales after India banned copying of patented drugs. According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford Healthcare and Syrio Pharma to sell drugs for chronic and acute cases.
A handful of the world's largest agricultural biotechnology companies are seeking hundreds of patents on gene-altered crops designed to withstand drought and other environmental stresses, part of a race for dominance in the potentially lucrative market for crops that can handle global warming, according to a report being released Tuesday.
This is a fascinating story of intellectual property rights (IPR) involving one of the greatest national parks in the world, a tiny bacterium found in its fetid bubbling springs and the millions of dollars it has helped to generate for a pharmaceutical giant in another continent.
In a recent opinion piece (
Microsoft is the most familiar term in the proprietary software industry. The company s penetration in people s minds is so deep that it is often considered the only player in the market. It is even mistaken as a software. <br><br> But this scenario
After consecutive litigation losses against Pfizer in its bid to grab a market share of the world's largest selling drug, Lipitor, Ranbaxy can now breathe easy. Last week, the Indian company got a shot in the arm, with the US Patent and Trademark Office (USPTO) issuing a a preliminary rejection of Pfizer's request for reissue of a patent for Lipitor. The verdict gives Ranbaxy hope to launch the cholesterol lowering drug Lipitor as early as March 2010.
Intellectual Property (IP) has always been a niche public policy area understood best by policy wonks and lawyers. Unless there is a major controversy, IP tends to escape public consciousness. But that is changing. Over the past few years campaigns to undermine IP have increased and are now reaching a fever pitch.
the struggle for global open standards has got tougher with India saying no to Microsoft's Office Open xml (ooxml) document format. The decision comes despite attempts by Microsoft to make the
on april 23, the Delhi High Court will hear a case that is being dubbed as a "conflict between commercial interests and public health'. There are two main players
The loom in Aruna Kumari's badly lit, mud-walled house in Epurupalem village runs from 5 a.m. to 11 p.m., with either Aruna or her husband working at it constantly. Her ageing grandmother contributes